OBI Pharma Signs $2 Billion ADC Deal with Novartis

OBI Pharma has entered into a collaboration and licensing agreement with Novartis to develop next-generation antibody-drug conjugates (ADCs) using OBI’s proprietary technology platforms. The agreement has a potential total value of more than $2 billion, making it a major partnership in the growing ADC drug development space.

Under the agreement, Novartis will receive exclusive worldwide rights to use OBI Pharma’s ADC-related patents and technical know-how for selected, undisclosed payload classes. These technologies will support the development of new ADC treatments using novel drug payloads.

As part of the collaboration, OBI Pharma will evaluate new linker approaches using Novartis’ payloads. Novartis will also have the option to expand the agreement to cover additional payload classes in the future.

OBI Pharma will receive an upfront payment of $30 million. The company is also eligible for additional development, regulatory and commercial milestone payments, which could bring the total deal value to more than $2 billion. In addition, OBI will receive tiered royalties on net sales of licensed products developed through the partnership.

The collaboration will make use of OBI’s Obrion ADC Technology Platform, which combines several proprietary technologies designed to improve the development and production of ADCs.

These include GlycOBI, a technology that helps attach drug molecules to antibodies at specific locations, supporting more consistent ADC production. The platform also includes EndoSymeOBI, an enzyme-based technology, and HYPrOBI, a linker technology designed to improve the stability and performance of ADCs.

OBI’s GlycOBI DUO technology also supports the development of dual-payload ADCs, which can carry two different drug molecules within a single antibody-based treatment.

Antibody-drug conjugates are a growing area of cancer research. These treatments combine the targeting ability of antibodies with powerful drug molecules to deliver treatment more directly to cancer cells while aiming to limit damage to healthy tissues.

Ya-Chi Chen, Acting Chief Executive Officer of OBI Pharma, said the agreement recognises the scientific and commercial potential of the company’s ADC technologies. She added that combining OBI’s expertise with Novartis’ resources and development capabilities could help advance new treatments for patients.

Shiva Malek, Global Head of Oncology, Biomedical Research at Novartis, said the collaboration supports the company’s strategy to develop innovative ADC treatments with novel payloads and potentially expand treatment options for patients.

Founded in 2002 and headquartered in Taiwan, OBI Pharma is a clinical-stage oncology company focused on developing cancer treatments and proprietary ADC technologies. The partnership with Novartis is expected to strengthen the company’s global presence and expand the use of its ADC platform in future cancer drug development.

You might also like